{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:27:52Z","timestamp":1793316472599,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"publisher","award":["CT58\/21"],"award-info":[{"award-number":["CT58\/21"]}],"id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"publisher","award":["PR3\/23-30834"],"award-info":[{"award-number":["PR3\/23-30834"]}],"id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"publisher","award":["PR17\/24-31948"],"award-info":[{"award-number":["PR17\/24-31948"]}],"id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00626"],"award-info":[{"award-number":["PI18\/00626"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00721"],"award-info":[{"award-number":["PI18\/00721"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10120-025-01689-5","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:28:30Z","timestamp":1764851310000},"page":"83-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hampered CD8\u2009+\u2009ILT2\u2009+\u2009T cell activation by HLA-G suggests a new immune checkpoint in gastric adenocarcinoma"],"prefix":"10.1007","volume":"29","author":[{"given":"Christian","family":"Vaquero-Yuste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Molina-Alejandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Guti\u00e9rrez-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"L\u00f3pez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Lasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remedios","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Arnaiz-Villena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2436-8585","authenticated-orcid":false,"given":"Jos\u00e9 Manuel","family":"Mart\u00edn-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"1689_CR1","doi-asserted-by":"publisher","first-page":"796054","DOI":"10.3389\/fimmu.2022.796054","volume":"13","author":"JM Mart\u00edn-Villa","year":"2022","unstructured":"Mart\u00edn-Villa JM, Vaquero-Yuste C, Molina-Alejandre M, Juarez I, Su\u00e1rez-Trujillo F, L\u00f3pez-Nares A, et al. HLA-G: too much or too little? Role in cancer and autoimmune disease. Front Immunol. 2022;13:796054. https:\/\/doi.org\/10.3389\/fimmu.2022.796054.","journal-title":"Front Immunol"},{"key":"1689_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"1689_CR3","doi-asserted-by":"publisher","first-page":"118110","DOI":"10.1016\/j.lfs.2020.118110","volume":"258","author":"K Mortezaee","year":"2020","unstructured":"Mortezaee K. Immune escape: a critical hallmark in solid tumors. Life Sci. 2020;258:118110.","journal-title":"Life Sci"},{"issue":"5","key":"1689_CR4","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044\u201360. https:\/\/doi.org\/10.3390\/curroncol29050247.","journal-title":"Curr Oncol"},{"key":"1689_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, G\u00f6genur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359\u201367.","journal-title":"Br J Cancer"},{"key":"1689_CR6","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3332\/ecancer.2020.1148","volume":"14","author":"S Morganti","year":"2020","unstructured":"Morganti S, Curigliano G. Combinations using checkpoint blockade to overcome resistance. Ecancermedicalscience. 2020;14:1148. https:\/\/doi.org\/10.3332\/ecancer.2020.1148.","journal-title":"Ecancermedicalscience"},{"key":"1689_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-40745-5","volume":"14","author":"S Hiltbrunner","year":"2023","unstructured":"Hiltbrunner S, Cords L, Kasser S, Freiberger SN, Kreutzer S, Toussaint NC, et al. Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype. Nat Commun. 2023;14:1\u201314.","journal-title":"Nat Commun"},{"key":"1689_CR8","doi-asserted-by":"publisher","first-page":"698677","DOI":"10.3389\/fimmu.2021.698677","volume":"12","author":"A Lin","year":"2021","unstructured":"Lin A, Yan W. HLA-G\/ILTs targeted solid cancer immunotherapy: opportunities and challenges. Front Immunol. 2021;12:698677. https:\/\/doi.org\/10.3389\/fimmu.2021.698677.","journal-title":"Front Immunol"},{"key":"1689_CR9","doi-asserted-by":"publisher","first-page":"679090","DOI":"10.3389\/fimmu.2021.679090","volume":"12","author":"QY Chen","year":"2021","unstructured":"Chen QY, Chen YX, Han QY, Zhang JG, Zhou WJ, Zhang X, et al. Prognostic significance of immune checkpoints HLA-G\/ILT-2\/4 and PD-L1 in colorectal cancer. Front Immunol. 2021;12:679090. https:\/\/doi.org\/10.3389\/fimmu.2021.679090.","journal-title":"Front Immunol"},{"issue":"6","key":"1689_CR10","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3390\/ijms23062925","volume":"23","author":"F Morandi","year":"2022","unstructured":"Morandi F, Airoldi I. HLA-G and other immune checkpoint molecules as targets for novel combined immunotherapies. Int J Mol Sci. 2022;23(6):2925. https:\/\/doi.org\/10.3390\/ijms23062925.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1689_CR11","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.3390\/ijms21124528","volume":"21","author":"D Krijgsman","year":"2020","unstructured":"Krijgsman D, Roelands J, Hendrickx W, Bedognetti D, Kuppen PJK. HLA-G: A new immune checkpoint in cancer? Int J Mol Sci. 2020;21(12):4528. https:\/\/doi.org\/10.3390\/ijms21124528.","journal-title":"Int J Mol Sci"},{"issue":"22","key":"1689_CR12","doi-asserted-by":"publisher","first-page":"8678","DOI":"10.3390\/ijms21228678","volume":"21","author":"JVD Attia","year":"2020","unstructured":"Attia JVD, Dessens CE, van de Water R, Houvast RD, Kuppen PJK, Krijgsman D. The molecular and functional characteristics of HLA-G and the interaction with its receptors: Where to intervene for cancer immunotherapy? Int J Mol Sci. 2020;21(22):8678. https:\/\/doi.org\/10.3390\/ijms21228678.","journal-title":"Int J Mol Sci"},{"key":"1689_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.it.2017.01.009","volume":"38","author":"LMR Ferreira","year":"2017","unstructured":"Ferreira LMR, Meissner TB, Tilburgs T, Strominger JL. HLA-G: at the interface of maternal-fetal tolerance. Trends Immunol. 2017;38:272\u201386.","journal-title":"Trends Immunol"},{"issue":"11","key":"1689_CR14","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.humimm.2003.08.346","volume":"64","author":"M Le Discorde","year":"2003","unstructured":"Le Discorde M, Moreau P, Sabatier P, Legeais J, Carosella ED. Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol. 2003;64(11):1039\u201344. https:\/\/doi.org\/10.1016\/j.humimm.2003.08.346.","journal-title":"Hum Immunol"},{"issue":"3","key":"1689_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1158\/0008-5472.CAN-07-2704","volume":"68","author":"M Urosevic","year":"2008","unstructured":"Urosevic M, Dummer R. Human leukocyte antigen-G and cancer immunoediting. Cancer Res. 2008;68(3):627\u201330. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2704.","journal-title":"Cancer Res"},{"issue":"9","key":"1689_CR16","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/ijc.28845","volume":"135","author":"L Loumagne","year":"2014","unstructured":"Loumagne L, Baudhuin J, Favier B, Montespan F, Carosella ED, Rouas-Freiss N. In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance. Int J Cancer. 2014;135(9):2107\u201317. https:\/\/doi.org\/10.1002\/ijc.28845.","journal-title":"Int J Cancer"},{"issue":"4","key":"1689_CR17","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.3892\/ol.2017.6784","volume":"14","author":"JA Rodr\u00edguez","year":"2017","unstructured":"Rodr\u00edguez JA. HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation. Oncol Lett. 2017;14(4):4415\u201327. https:\/\/doi.org\/10.3892\/ol.2017.6784.","journal-title":"Oncol Lett"},{"key":"1689_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12558-015-0361-6","volume":"7","author":"O Oucherif","year":"2015","unstructured":"Oucherif O, Naimi D. Function of HLA-G in cancer immunoediting and its clinical benefits. J Afr Cancer. 2015;7:132\u20139.","journal-title":"J Afr Cancer"},{"key":"1689_CR19","doi-asserted-by":"publisher","first-page":"8856","DOI":"10.1073\/pnas.1431057100","volume":"100","author":"M Shiroishi","year":"2003","unstructured":"Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A. 2003;100:8856\u201361.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1689_CR20","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.4049\/jimmunol.166.4.2514","volume":"166","author":"J Dietrich","year":"2001","unstructured":"Dietrich J, Cella M, Colonna M. Ig-like transcript 2 (ILT2)\/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization. J Immunol. 2001;166(4):2514\u201321. https:\/\/doi.org\/10.4049\/jimmunol.166.4.2514.","journal-title":"J Immunol"},{"issue":"8","key":"1689_CR21","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/intimm\/11.8.1351","volume":"11","author":"FA Le Gal","year":"1999","unstructured":"Le Gal FA, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol. 1999;11(8):1351\u20136. https:\/\/doi.org\/10.1093\/intimm\/11.8.1351.","journal-title":"Int Immunol"},{"issue":"8","key":"1689_CR22","doi-asserted-by":"publisher","first-page":"e22776","DOI":"10.1371\/journal.pone.0022776","volume":"6","author":"F Ketroussi","year":"2011","unstructured":"Ketroussi F, Giuliani M, Bahri R, Azzarone B, Charpentier B, Durrbach A. Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway. PLoS ONE. 2011;6(8):e22776. https:\/\/doi.org\/10.1371\/journal.pone.0022776.","journal-title":"PLoS ONE"},{"key":"1689_CR23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.4049\/jimmunol.176.3.1331","volume":"176","author":"R Bahri","year":"2006","unstructured":"Bahri R, Hirsch F, Josse A, Rouas-Freiss N, Bidere N, Vasquez A, et al. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol. 2006;176:1331\u20139.","journal-title":"J Immunol"},{"issue":"6","key":"1689_CR24","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.20112741","volume":"209","author":"T Yokosuka","year":"2012","unstructured":"Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201\u201317. https:\/\/doi.org\/10.1084\/jem.20112741.","journal-title":"J Exp Med"},{"key":"1689_CR25","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1186\/s12864-018-5236-2","volume":"19","author":"JR Stevens","year":"2018","unstructured":"Stevens JR, Herrick JS, Wolff RK, Slattery ML. Power in pairs: assessing the statistical value of paired samples in tests for differential expression. BMC Genomics. 2018;19:953.","journal-title":"BMC Genomics"},{"issue":"6","key":"1689_CR26","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1080\/02664763.2020.1864813","volume":"49","author":"Q Qi","year":"2020","unstructured":"Qi Q, Yan L, Tian L. Analyzing partially paired data: When can the unpaired portion(s) be safely ignored? J Appl Stat. 2020;49(6):1402\u201320.","journal-title":"J Appl Stat"},{"issue":"11","key":"1689_CR27","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/sim.4200","volume":"30","author":"PC Austin","year":"2011","unstructured":"Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. Stat Med. 2011;30(11):1292\u2013301. https:\/\/doi.org\/10.1002\/sim.4200.","journal-title":"Stat Med"},{"issue":"2","key":"1689_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cellimm.2006.02.007","volume":"238","author":"M Lopez-Santalla","year":"2005","unstructured":"Lopez-Santalla M, Krishnan S, Valeri AP, Aguilera-Montilla N, Fisher CU, Perez-Blas M, et al. Defective CD3zeta chain expression in Herpesvirus saimiri (HVS)-derived T-cell lines in gastric adenocarcinoma. Cell Immunol. 2005;238(2):113\u201322. https:\/\/doi.org\/10.1016\/j.cellimm.2006.02.007.","journal-title":"Cell Immunol"},{"key":"1689_CR29","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s00262-005-0072-z","volume":"55","author":"M L\u00f3pez-Santalla","year":"2006","unstructured":"L\u00f3pez-Santalla M, Valeri AP, P\u00e9rez-Blas M, Aguilera-Montilla N, Guti\u00e9rrez A, Lasa I, et al. Expression of CD45 and proliferative response to CD3 as suitable classification markers of patients with gastric adenocarcinoma. Cancer Immunol Immunother. 2006;55:744\u20138.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1689_CR30","doi-asserted-by":"publisher","first-page":"1039458","DOI":"10.1155\/2020\/1039458","volume":"2020","author":"A Aguinaga-Barrilero","year":"2020","unstructured":"Aguinaga-Barrilero A, Castro-S\u00e1nchez P, Ju\u00e1rez I, Guti\u00e9rrez-Calvo A, Rodr\u00edguez-P\u00e9rez N, Lopez A, et al. Defects at the posttranscriptional level account for the low TCR\u03b6 chain expression detected in gastric cancer independently of caspase-3 activity. J Immunol Res. 2020;2020(1):1039458. https:\/\/doi.org\/10.1155\/2020\/1039458.","journal-title":"J Immunol Res"},{"issue":"1","key":"1689_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.clim.2007.12.002","volume":"127","author":"M Czesnikiewicz-Guzik","year":"2008","unstructured":"Czesnikiewicz-Guzik M, Lee WW, Cui D, Hiruma Y, Lamar DL, Yang ZZ, et al. T cell subset-specific susceptibility to aging. Clin Immunol. 2008;127(1):107\u201318. https:\/\/doi.org\/10.1016\/j.clim.2007.12.002.","journal-title":"Clin Immunol"},{"key":"1689_CR32","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1159\/000485819","volume":"44","author":"R Wan","year":"2017","unstructured":"Wan R, Wang ZW, Li H, Peng XD, Liu GY, Ou JM, et al. Human leukocyte antigen-G inhibits the anti-tumor effect of natural killer cells via immunoglobulin-like transcript 2 in gastric cancer. Cell Physiol Biochem. 2017;44:1828\u201341.","journal-title":"Cell Physiol Biochem"},{"key":"1689_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00428-018-2379-0","volume":"473","author":"G Murdaca","year":"2018","unstructured":"Murdaca G, Calamaro P, Lantieri F, Pigozzi S, Mastracci L, Grillo F, et al. HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact. Virchows Arch. 2018;473:425\u201333.","journal-title":"Virchows Arch"},{"issue":"10","key":"1689_CR34","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1158\/2326-6066.CIR-18-0764","volume":"7","author":"C Dumont","year":"2019","unstructured":"Dumont C, Jacquier A, Verine J, Noel F, Goujon A, Wu CL, et al. CD8+PD-1-ILT2+ T cells are an intratumoral cytotoxic population selectively inhibited by the immune-checkpoint HLA-G. Cancer Immunol Res. 2019;7(10):1619\u201332. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0764.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"1689_CR35","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.4049\/jimmunol.1801472","volume":"203","author":"A Kim","year":"2019","unstructured":"Kim A, Han C, Driver I, Olow A, Sewell AK, Zhang Z, et al. LILRB1 blockade enhances bispecific T cell engager antibody-induced tumor cell killing by effector CD8+ T cells. J Immunol. 2019;203(4):1076\u201387. https:\/\/doi.org\/10.4049\/jimmunol.1801472.","journal-title":"J Immunol"},{"key":"1689_CR36","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.cell.2014.10.026","volume":"159","author":"JJC Thome","year":"2014","unstructured":"Thome JJC, Yudanin N, Ohmura Y, Kubota M, Grinshpun B, Sathaliyawala T, et al. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell. 2014;159:814\u201328.","journal-title":"Cell"},{"issue":"12","key":"1689_CR37","doi-asserted-by":"publisher","first-page":"7223","DOI":"10.4049\/jimmunol.173.12.7223","volume":"173","author":"N Anfossi","year":"2004","unstructured":"Anfossi N, Doisne J, Peyrat M, Ugolini S, Bonnaud O, Bossy D, et al. Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells. J Immunol. 2004;173(12):7223\u20139. https:\/\/doi.org\/10.4049\/jimmunol.173.12.7223.","journal-title":"J Immunol"},{"issue":"4","key":"1689_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.humimm.2020.02.001","volume":"81","author":"A Jacquier","year":"2020","unstructured":"Jacquier A, Dumont C, Carosella ED, Rouas-Freiss N, LeMaoult J. Cytometry-based analysis of HLA-G functions according to ILT2 expression. Hum Immunol. 2020;81(4):168\u201377. https:\/\/doi.org\/10.1016\/j.humimm.2020.02.001.","journal-title":"Hum Immunol"},{"issue":"10","key":"1689_CR39","doi-asserted-by":"publisher","first-page":"e1353856","DOI":"10.1080\/2162402X.2017.1353856","volume":"6","author":"M Villa-\u00c1lvarez","year":"2017","unstructured":"Villa-\u00c1lvarez M, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, L\u00f3pez-Soto A, Payer AR, Gonzalez-Garcia E, et al. Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia. Oncoimmunology. 2017;6(10):e1353856. https:\/\/doi.org\/10.1080\/2162402X.2017.1353856.","journal-title":"Oncoimmunology"},{"issue":"9","key":"1689_CR40","doi-asserted-by":"publisher","first-page":"e004859","DOI":"10.1136\/jitc-2022-004859","volume":"10","author":"I Mandel","year":"2022","unstructured":"Mandel I, Haves Ziv D, Goldshtein I, Peretz T, Alishekevitz D, Dror AF, et al. BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression. J Immunother Cancer. 2022;10(9):e004859. https:\/\/doi.org\/10.1136\/jitc-2022-004859.","journal-title":"J Immunother Cancer"},{"key":"1689_CR41","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"1689_CR42","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173(2):945\u201354. https:\/\/doi.org\/10.4049\/jimmunol.173.2.945.","journal-title":"J Immunol"},{"key":"1689_CR43","doi-asserted-by":"publisher","first-page":"1240275","DOI":"10.3389\/fimmu.2023.1240275","volume":"14","author":"T Zeller","year":"2023","unstructured":"Zeller T, M\u00fcnnich IA, Windisch R, Hilger P, Schewe DM, Humpe A, et al. Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer. Front Immunol. 2023;14:1240275.","journal-title":"Front Immunol"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01689-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:53:18Z","timestamp":1769151198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01689-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01689-5","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients. Ethics approval number for this study is CI 19\/090-E-BC, provided by the Ethics Committee of Hospital Cl\u00ednico San Carlos, Madrid, Spain.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}